Compare Novo Nordisk A/S (NVO) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Roblox Corp — how do they compare? Novo Nordisk A/S trades at $45.07 (market cap $200.69B), while Roblox Corp trades at $44.66 (market cap $32.02B). The key difference: Novo Nordisk A/S is far larger — about 6.3× Roblox Corp's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| NVO | RBLX | |
|---|---|---|
Market Cap | $200.69B | $32.02B |
Sector | Health | Media |
52-Week High | $63.98 | $141.56 |
52-Week Low | $35.29 | $35.54 |
Enterprise Value | $215.49B | $30.84B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Roblox (RBLX) trades at $44.82, up 3.49% today, with a bullish technical signal and strong revenue growth to $4.89B in 2025, though net losses persist. Recent earnings beats and positive cash flow trends contrast with high valuation ratios and regulatory scrutiny. The stock is near its consensus price target of $45.71, with support at $43 and resistance at $46.
Outlook: Long-term growth potential via user engagement and creator economy is tempered by profitability challenges and child-safety regulations. Risks include sustained losses and competitive pressure, but analyst sentiment leans slightly bullish with 44.74% buy ratings. Investors should weigh revenue momentum against margin improvement needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
